An Open-label, Randomized, Controlled, Multicenter Phase III Trial to Compare Cetuximab in Combination With FOLFOX-4 Versus FOLFOX-4 Alone in the First Line Treatment of Metastatic Colorectal Cancer in Chinese Subjects With RAS Wild-type Status.

Trial Profile

An Open-label, Randomized, Controlled, Multicenter Phase III Trial to Compare Cetuximab in Combination With FOLFOX-4 Versus FOLFOX-4 Alone in the First Line Treatment of Metastatic Colorectal Cancer in Chinese Subjects With RAS Wild-type Status.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 12 Sep 2017

At a glance

  • Drugs Cetuximab (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
  • Indications Colorectal cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms TAILOR
  • Sponsors Merck KGaA
  • Most Recent Events

    • 12 Sep 2017 Results assessing Quality of life (QoL) from patients with RAS wild-type metastatic colorectal cancer (n=393) presented at the 42nd European Society for Medical Oncology Congress
    • 21 Jul 2017 Planned End Date changed from 1 May 2017 to 30 Dec 2018.
    • 02 Mar 2017 According to a Merck KGaA media release, based on the data from this and other three studies (CTP: 8930,15696 and 37756) the UK National Institute for Health and Care Excellence (NICE) has issued a positive Final Appraisal Determination (FAD) recommending the routine National Health Service (NHS) use of Erbitux (cetuximab) in combination with either FOLFIRI or FOLFOX as a first-line treatment for patients with RAS wild-type metastatic colorectal cancer (mCRC).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top